Parse Biosciences, a Seattle, WA-based provider of accessible and scalable single cell sequencing solutions, acquired Biomage, a Glasgow, UK-based data analysis software company.
The amount of the deal was not disclosed.
With the acquisition, Parse Biosciences will expand its offerings. All current Biomage staff members are being integrated into the existing Parse team.
Led by CEO Adam Kurkiewicz, Biomage hosts and supports a large community instance of Cellenics®, a cloud-based single cell RNA sequencing data analysis platform. The platform brings analysis tools to researchers without the need for bioinformatics expertise. Since launching the platform in 2021, the company has contributed to reduce average analysis times from six months to two weeks. The platform has a user base of nearly 4,000 researchers globally, with approximately 200 scientists accessing the platform daily.
Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing, its approach is enabling discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.
Founded based on technology invented at the University of Washington, Parse has raised over $100m and is used by over 1,000 labs across the world. Its portfolio of products includes Evercode Whole Transcriptome, Evercode TCR, Gene Capture, and a software tool for data analysis.
FinSMEs
17/01/2024